Topic: CD005139 

Title: Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 

Objective: 
To investigate ocular and systemic effects of, and quality of life associated with, intravitreous injection of anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) versus no anti‐VEGF treatment for patients with neovascular AMD To compare the relative effects of one of these anti‐VEGF agents versus another when administered in comparable dosages and regimens 

